SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-326601
Filing Date
2019-12-31
Accepted
2019-12-31 16:05:11
Documents
15
Period of Report
2019-12-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d859705d8k.htm   iXBRL 8-K 31142
2 EX-10.1 d859705dex101.htm EX-10.1 111969
3 EX-10.2 d859705dex102.htm EX-10.2 47464
4 EX-10.3 d859705dex103.htm EX-10.3 102556
  Complete submission text file 0001193125-19-326601.txt   484867

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20191230.xsd EX-101.SCH 3052
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20191230_lab.xml EX-101.LAB 18139
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20191230_pre.xml EX-101.PRE 11396
13 EXTRACTED XBRL INSTANCE DOCUMENT d859705d8k_htm.xml XML 3337
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 191319522
SIC: 2834 Pharmaceutical Preparations